Phase 4 N=123 Metoclopramide Versus Ketorolac for Tension-type Headache
Headache
Primary: Change in Pain Score — 3.8; 5.1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=165 Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
Tension-Type Headache
Primary: Number of Subjects Pain Free — 21; 20; 21; 19 Participants
Phase 3 N=200 Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache
Pain
Primary: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet — 11.2; 10.8 Units on a scale…
Phase 3 N=226 Ibuprofen Sodium Tension Headache Study
Pain
Primary: Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet — 9.6; 3.5 units on scale…
N/A N=193 Cognitive-Behavior Therapy for Posttraumatic Headache
Post-traumatic Headache · PTSD
Primary: Headache-related Disability Scores on the Headache Impact Test 6 (HIT-6) — 66.1; 66.1; 65.2; 61.9 score on a scale — p=<0.001
N/A N=216 A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the Treatment of Tension-type Headaches (TTH) in Healthy Participants
Healthy Volunteers · Tension-type Headache
Primary: Cohort 2: Time-weighted Sum of Pain Intensity Difference From Baseline (0 Hour) to 2 Hours (SPID 0-2) Post-dose — -210 units on a scale
N/A N=79 Managing Mild Traumatic Brain Injury Related Headaches With Repetitive Transcranial Magnetic Stimulation
Traumatic Brain Injury (TBI)
Primary: Number of Headache Days Per Week — 4.2; 4.6; 3.1; 4.3 days/week — p=<0.000
Phase 2 N=40 Sumatriptan as Treatment for Post-traumatic Headache
Post-traumatic Headache
Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079
Phase 4 N=79 Treatment of Insomnia in Migraineurs
Insomnia · Migraine
Primary: Total Sleep Time — 5.4; 5.5; 6.3; 6.1 hours — p=0.33
N/A N=40 Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache
Chronic Daily Headache
Primary: Reduction in Headache Intensity — 6; 4; 1; 3 Participants
N/A N=57 TelemEdiciNe-bAsed Cognitive TherapY for Migraines
Migraine Headache
Primary: Number of Headache Days at 3 Months — 18.17; 19.19; 16.47; 18.26 headache days — p=0.61
Phase 2 N=296 Continuous Treatment Study of Topiramate in Migraine Participants
Migraine
Primary: Number of Participants With Adverse Events — 110; 85; 79 Participants
N/A N=29 Improving Functions in MTBI Patients With Headache by rTMS
TBI (Traumatic Brain Injury)
Primary: Percent Change in Composite Score of Debilitating Headache (Intensity x Duration x Frequency) — -55.3; -1.7; -58.4; -10 percent change from baseline — p=<0.0001
N/A N=187 The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Acute Migraine
Primary: Proportion of Subjects Reporting Reduction of Migraine Headache Pain at 2 Hours From Treatment Initiation — 30; 22 Participants — p=0.018
Phase 2 N=50 Amitriptyline to Prevent Headache After Traumatic Brain Injury
Brain Injuries · Post-Traumatic Headache
Primary: Frequency of Headaches — 10 Participants — p=.101
N/A N=102 A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.
Cluster Headache
Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks
Phase 2 N=45 Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
New Daily Persistent Headache (NDPH)
Primary: Pain Intensity — 5.82; 4.92 score on a scale
N/A N=45 Do Patients With Chronic Daily Headache Have Continuous Headache or Moments of Headache Relief?
Chronic Daily Headache
Primary: Number of Subjects With Daily Headache Who Have Continuous Headache — 18; 27 participants
N/A N=23 Intracranial Pressure in Experimental Models of Headache
High Altitude Headache
Primary: Change in Optic Nerve Sheath Diameter by Ultrasonography — 0.02; 0.02 mm — p=0.98
N/A N=48 RELAXaHEAD for Headache Patients (Phase II)
Migraine · Headache · Multiple Sclerosis
Primary: Number of Patients Enrolled in the Study — 24; 24 Participants
N/A N=191 Managing Temporomandibular Disorder (TMD) Symptoms
Temporomandibular Joint Disorders
Primary: Characteristic Pain Intensity (Characteristic Intensity of Facial Pain) — 3.1; 2.9; 3.6 units on a scale — p=0.19
N/A N=759 IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headache Disorders, Primary · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Patients With Significant Pain Reduction — 90.3 percentage of participants
N/A N=30 SinuSonic for ETD and Facial Pain: Acoustic Vibration + Oscillating Expiratory Pressure
Eustachian Tube Dysfunction · Facial Pain
Primary: Eustachian Tube Dysfunction (ETD) Symptom Visual Analog Scale (VAS) - Total Score — 59.6 score on a scale
Phase 4 N=62 Acute Headache Treatment in Pregnancy: Occipital Nerve Block vs PO Acetaminophen With Caffeine
Headache · Pregnancy Related · Occipital Nerve Block
Primary: Number of Participants With Response to Occipital Nerve Block in Pregnancy — 20; 16 Participants — p=0.30
N/A N=26 Remotely Supervised tDCS for Persistent Post-traumatic Headache
Persistent Post Traumatic Headache · Mild Traumatic Brain Injury
Primary: Change From Baseline in the Number of Moderate-to-Severe Headache Days Per Month — -2.5; 2.3; -3.9; 1.2 Days per Month
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
N/A N=91 Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department
Headache
Primary: Time to Relief (Min) — 92.2; 83.9; 35.4 Minutes
N/A N=24 Motor Cortex as a Research & Therapeutic Target in TMD
Temporomandibular Joint Disorders
Primary: Number of Participants With Pain Relief as Measured by Visual Analog Scale (VAS) Decrease of 50% or Greater From Baseline — 4; 9 participants
N/A N=459 A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Migraine Disorders · Headache
Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants
N/A N=24 Duloxetine for Treatment of Painful Temporomandibular Joint Disorder
Temporomandibular Joint Disorders
Primary: Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. — 42.9; 51.4; 30.4; 44 units on a scale